Margery H. Mark

2.1k total citations
31 papers, 1.1k citations indexed

About

Margery H. Mark is a scholar working on Neurology, Cognitive Neuroscience and Psychiatry and Mental health. According to data from OpenAlex, Margery H. Mark has authored 31 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Neurology, 7 papers in Cognitive Neuroscience and 7 papers in Psychiatry and Mental health. Recurrent topics in Margery H. Mark's work include Parkinson's Disease Mechanisms and Treatments (26 papers), Neurological disorders and treatments (19 papers) and Autism Spectrum Disorder Research (7 papers). Margery H. Mark is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (26 papers), Neurological disorders and treatments (19 papers) and Autism Spectrum Disorder Research (7 papers). Margery H. Mark collaborates with scholars based in United States, Netherlands and Canada. Margery H. Mark's co-authors include Matthew Menza, Jacob I. Sage, Roseanne D. Dobkin, Michael A. Gara, Karina Bienfait, Jill Harkavy‐Friedman, Lesley A. Allen, Humberto Marín, Allison Dicke and Jacob Sage and has published in prestigious journals such as American Journal of Psychiatry, Neurology and Annals of Neurology.

In The Last Decade

Margery H. Mark

31 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Margery H. Mark United States 19 895 238 200 189 180 31 1.1k
G. Fuchs Germany 17 1.0k 1.2× 387 1.6× 248 1.2× 146 0.8× 191 1.1× 38 1.4k
Antonino Cannas Italy 21 894 1.0× 154 0.6× 158 0.8× 254 1.3× 104 0.6× 60 1.2k
Karina Bienfait United States 15 824 0.9× 193 0.8× 289 1.4× 148 0.8× 159 0.9× 17 1.1k
Stacy Horn United States 13 1.1k 1.3× 226 0.9× 298 1.5× 245 1.3× 117 0.7× 19 1.5k
Florence Ghika-Schmid Switzerland 14 588 0.7× 279 1.2× 230 1.1× 207 1.1× 133 0.7× 20 1.1k
María José Catalán Spain 13 853 1.0× 198 0.8× 227 1.1× 159 0.8× 253 1.4× 21 1.1k
Elena Torre Italy 17 799 0.9× 248 1.0× 441 2.2× 165 0.9× 269 1.5× 21 1.2k
Chiara Siri Italy 20 1.2k 1.3× 294 1.2× 283 1.4× 172 0.9× 161 0.9× 37 1.4k
George M. Ringholz United States 7 932 1.0× 165 0.7× 335 1.7× 318 1.7× 126 0.7× 8 1.6k
Anna Sauerbier United Kingdom 23 1.4k 1.6× 253 1.1× 228 1.1× 115 0.6× 143 0.8× 56 1.6k

Countries citing papers authored by Margery H. Mark

Since Specialization
Citations

This map shows the geographic impact of Margery H. Mark's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Margery H. Mark with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Margery H. Mark more than expected).

Fields of papers citing papers by Margery H. Mark

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Margery H. Mark. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Margery H. Mark. The network helps show where Margery H. Mark may publish in the future.

Co-authorship network of co-authors of Margery H. Mark

This figure shows the co-authorship network connecting the top 25 collaborators of Margery H. Mark. A scholar is included among the top collaborators of Margery H. Mark based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Margery H. Mark. Margery H. Mark is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mark, Margery H., Rohit Dhall, Sherron Kell, et al.. (2015). Summary of safety from clinical trial experience with IPX066, extended-release carbidopa-levodopa, in Parkinson’s disease (P1.184). Neurology. 84(14_supplement). 2 indexed citations
2.
Dobkin, Roseanne D., Alexander I. Tröster, Lesley A. Allen, et al.. (2013). Neuropsychological Outcomes After Psychosocial Intervention for Depression in Parkinson’s Disease. Journal of Neuropsychiatry. 26(1). 57–63. 17 indexed citations
3.
Dobkin, Roseanne D., Lesley A. Allen, Jill Harkavy‐Friedman, et al.. (2012). Predictors of treatment response to cognitive-behavioral therapy for depression in Parkinson's disease.. Journal of Consulting and Clinical Psychology. 80(4). 694–699. 51 indexed citations
4.
Dobkin, Roseanne D., Matthew Menza, Lesley A. Allen, et al.. (2011). Telephone-Based Cognitive–Behavioral Therapy for Depression in Parkinson Disease. Journal of Geriatric Psychiatry and Neurology. 24(4). 206–214. 65 indexed citations
5.
Dobkin, Roseanne D., Matthew Menza, Lesley A. Allen, et al.. (2011). Cognitive-Behavioral Therapy for Depression in Parkinson's Disease: A Randomized, Controlled Trial. American Journal of Psychiatry. 168(10). 1066–1074. 212 indexed citations
6.
Dobkin, Roseanne D., Matthew Menza, Karina Bienfait, et al.. (2010). The Impact of Antidepressant Treatment on Cognitive Functioning in Depressed Patients with Parkinson’s Disease. Journal of Neuropsychiatry. 22(2). 188–195. 27 indexed citations
7.
Bienfait, Karina, Matthew Menza, Margery H. Mark, & Roseanne D. Dobkin. (2010). Impulsive smoking in a patient with Parkinson’s disease treated with dopamine agonists. Journal of Clinical Neuroscience. 17(4). 539–540. 21 indexed citations
8.
Dobkin, Roseanne D., Matthew Menza, Karina Bienfait, et al.. (2010). Depression in Parkinson's Disease: Symptom Improvement and Residual Symptoms After Acute Pharmacologic Management. American Journal of Geriatric Psychiatry. 19(3). 222–229. 29 indexed citations
9.
Menza, Matthew, Roseanne D. Dobkin, Humberto Marín, et al.. (2009). The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease. Movement Disorders. 24(9). 1325–1332. 67 indexed citations
10.
Golbe, Lawrence I., Alice Lazzarini, William G. Johnson, et al.. (2001). The tau A0 allele in Parkinson's disease. Movement Disorders. 16(3). 442–447. 47 indexed citations
11.
Mark, Margery H.. (2001). Lumping and splitting the parkinson plus syndromes. Neurologic Clinics. 19(3). 607–627. 24 indexed citations
12.
Mark, Margery H., et al.. (1999). Quetiapine as an alternative to clozapine in the treatment of dopamimetic psychosis in patients with Parkinson's disease.. Annals of Clinical Psychiatry. 11(3). 141–144. 38 indexed citations
13.
Syed, Nadir Ali, John Murphy, Thomas Zimmerman, Margery H. Mark, & Jacob I. Sage. (1998). Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease. Movement Disorders. 13(2). 336–338. 75 indexed citations
14.
Sage, Jacob I. & Margery H. Mark. (1996). Practical Neurology of the Elderly. Medical Entomology and Zoology. 4 indexed citations
15.
Sage, Jacob I. & Margery H. Mark. (1995). Drenching sweats as an off phenomenon in parkinson's disease: Treatment and relation to plasma levodopa profile. Annals of Neurology. 37(1). 120–122. 47 indexed citations
16.
Zimmerman, Thomas, Jacob I. Sage, Anthony E. Lang, & Margery H. Mark. (1994). Severe evening dyskinesias in advanced Parkinson's disease: Clinical description, relation to plasma levodopa, and treatment. Movement Disorders. 9(2). 173–177. 15 indexed citations
17.
Sage, Jacob I. & Margery H. Mark. (1994). Diagnosis and treatment of parkinson’s disease in the elderly. Journal of General Internal Medicine. 9(10). 583–589. 4 indexed citations
18.
Sage, Jacob I. & Margery H. Mark. (1991). Nighttime levodopa infusions to treat motor fluctuations in advanced parkinson's disease: Preliminary observations. Annals of Neurology. 30(4). 616–617. 16 indexed citations
19.
Mark, Margery H., et al.. (1991). Isolated lingual/palatal dystonia. Movement Disorders. 6(2). 177–179. 4 indexed citations
20.
Sage, Jacob I. & Margery H. Mark. (1988). Comparison of Controlled-Release Sinemet (CR4) and Standard Sinemet (25 mg/100 mg) in Advanced Parkinsonʼs Disease. Clinical Neuropharmacology. 11(2). 174–179. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by G. Fuchs Breakdown of academic impact, for papers by Antonino Cannas Breakdown of academic impact, for papers by Karina Bienfait Breakdown of academic impact, for papers by Stacy Horn Breakdown of academic impact, for papers by Florence Ghika-Schmid Breakdown of academic impact, for papers by María José Catalán Breakdown of academic impact, for papers by Elena Torre Breakdown of academic impact, for papers by Chiara Siri Breakdown of academic impact, for papers by George M. Ringholz Breakdown of academic impact, for papers by Anna Sauerbier
Rankless by CCL
2026